EUVIMEDEUVIMED entdecken
Crossref

Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy

Meryl Colton, Enkhtsetseg Purev, Bradley Haverkos, Steven Bair, Jagar Jasem, Allison Jacob, Manali Kamdar

Clinical Lymphoma Myeloma and Leukemia · 2024-11 · 24 (11) · 778-782

DOI: 10.1016/j.clml.2024.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-11. Verfasst von Meryl Colton und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO. Electronic address:…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveHumansMaleFemaleMiddle AgedAgedRetrospective StudiesLymphoma, B-CellAntigens, CD19Neoplasm, ResidualPilot ProjectsPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

Cell free DNA (ctDNA)Large B cell lymphoma (LBCL)Minimal residual disease (MRD)Molecular disease monitoringTisagenlecleucel

Substanzen

Antigens, CD19

Autor:innen und Institutionen

  • Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO. Electronic address: Meryl.colton@cuanschutz.edu.
  • Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO.
  • Adaptive Biotechnologies, Seattle WA.

Förderung

  • Novartis Pharmaceuticals Corp

Zitieren

APA

Colton, M., Purev, E., Haverkos, B., Bair, S., Jasem, J., Jacob, A., & Kamdar, M. (2024). Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Clinical Lymphoma Myeloma and Leukemia, 24(11), 778-782. https://doi.org/10.1016/j.clml.2024.06.006

Vancouver

Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, et al. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Clinical Lymphoma Myeloma and Leukemia. 2024;24(11):778-782. doi:10.1016/j.clml.2024.06.006

BibTeX
@article{Colton2024,
  author = {Colton, Meryl and Purev, Enkhtsetseg and Haverkos, Bradley and Bair, Steven and Jasem, Jagar and Jacob, Allison and Kamdar, Manali},
  title = {Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {11},
  pages = {778--782},
  doi = {10.1016/j.clml.2024.06.006}
}
Kostenlos starten →